Literature DB >> 28476914

Antimicrobial susceptibility in Neisseria gonorrhoeae isolates from five sentinel surveillance sites in Zimbabwe, 2015-2016.

Ahmed S Latif1, Lovemore Gwanzura2, Anna Machiha3, Francis Ndowa3, Andrew Tarupiwa4, Muchaneta Gudza-Mugabe4, Fungai D Shukusho4, Christine Chakanyuka Musanhu5, Teodora Wi6, Magnus Unemo7.   

Abstract

OBJECTIVES: Gonorrhoea and antimicrobial resistance (AMR) in Neisseria gonorrhoeae are major public health concerns worldwide. Enhanced AMR surveillance for gonococci is essential globally. In Zimbabwe, very limited gonococcal AMR data were reported. Our aims were to (i) implement quality-assured gonococcal AMR surveillance in Zimbabwe and (ii) investigate gonococcal AMR at five health centres in 2015-2016.
METHODS: Gonococcal isolates from 104 men with urethral discharge were tested for susceptibility to kanamycin, ceftriaxone, cefixime, ciprofloxacin and azithromycin using Etest.
RESULTS: All isolates (102 possible to test) were susceptible to ceftriaxone and cefixime. The level of resistance (intermediate resistance) to kanamycin and ciprofloxacin was 2.0% (2.0%) and 18.6% (27.5%), respectively. The two kanamycin-resistant isolates (R≥128 mg/L) had a kanamycin minimum inhibitory concentration (MIC) of >256 mg/L. The ciprofloxacin resistance ranged from 9.5% to 30.8% in the five sentinel sites. Only 10 (9.6%) of the isolates were tested for susceptibility to azithromycin and 1 (10.0%) was resistant (MIC=4 mg/L).
CONCLUSIONS: The emergence of multidrug-resistant gonorrhoea internationally is a major public health concern and gonococcal AMR surveillance is crucial globally. In Zimbabwe, gonococcal AMR surveillance has now been implemented and quality assured according to WHO standards. The results of this first surveillance will be used to directly inform revisions of the national treatment guidelines. It is imperative to further strengthen the surveillance of gonococcal AMR, and ideally also treatment failures, in Zimbabwe and most countries in the WHO African region, which requires continuous national and international support, including technical support, and political and financial commitment. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  AFRICA; ANTIMICROBIAL RESISTANCE; GONORRHOEA; NEISSERIA GONORRHOEA; TREATMENT

Mesh:

Substances:

Year:  2017        PMID: 28476914     DOI: 10.1136/sextrans-2016-053090

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  9 in total

Review 1.  World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts.

Authors:  Magnus Unemo; Monica M Lahra; Michelle Cole; Patricia Galarza; Francis Ndowa; Irene Martin; Jo-Anne R Dillon; Pilar Ramon-Pardo; Gail Bolan; Teodora Wi
Journal:  Sex Health       Date:  2019-09       Impact factor: 2.706

2.  Molecular screening for Neisseria gonorrhoeae antimicrobial resistance markers in Nigerian men who have sex with men and transgender women.

Authors:  Justin Hardick; Trevor A Crowell; Kara Lombardi; Akindiran Akintunde; Sunday Odeyemi; Andrew Ivo; George Eluwa; Jean Njab; Stefan D Baral; Rebecca G Nowak; Thomas C Quinn; Kent Barbian; Sarah Anzick; Sylvia Adebajo; Manhattan E Charurat; Julie Ake; Charlotte A Gaydos
Journal:  Int J STD AIDS       Date:  2018-07-04       Impact factor: 1.359

Review 3.  The antimicrobial resistance travel tool, an interactive evidence-based educational tool to limit antimicrobial resistance spread.

Authors:  Fabiana Arieti; Alessia Savoldi; Nithya Babu Rejendran; Marcella Sibani; Maela Tebon; Maria Diletta Pezzani; Anna Gorska; Teresa M Wozniak; Evelina Tacconelli
Journal:  J Travel Med       Date:  2022-07-14       Impact factor: 39.194

Review 4.  Mechanism of action, resistance, synergism, and clinical implications of azithromycin.

Authors:  Mohsen Heidary; Ahmad Ebrahimi Samangani; Abolfazl Kargari; Aliakbar Kiani Nejad; Ilya Yashmi; Moloudsadat Motahar; Elahe Taki; Saeed Khoshnood
Journal:  J Clin Lab Anal       Date:  2022-04-21       Impact factor: 3.124

5.  Susceptibility of Neisseria gonorrhoeae to azithromycin and ceftriaxone in China: A retrospective study of national surveillance data from 2013 to 2016.

Authors:  Yue-Ping Yin; Yan Han; Xiu-Qin Dai; He-Ping Zheng; Shao-Chun Chen; Bang-Yong Zhu; Gang Yong; Na Zhong; Li-Hua Hu; Wen-Ling Cao; Zhong-Jie Zheng; Feng Wang; Qi Zhi; Xiao-Yu Zhu; Xiang-Sheng Chen
Journal:  PLoS Med       Date:  2018-02-06       Impact factor: 11.069

6.  Surveillance systems to monitor antimicrobial resistance in Neisseria gonorrhoeae: a global, systematic review, 1 January 2012 to 27 September 2020.

Authors:  Nicholas A Medland; Ye Zhang; Praveena Gunaratnam; David A Lewis; Basil Donovan; David M Whiley; Rebecca J Guy; John M Kaldor
Journal:  Euro Surveill       Date:  2022-05

7.  A systematic review of antimicrobial resistance in Neisseria gonorrhoeae and Mycoplasma genitalium in sub-Saharan Africa.

Authors:  Collins Iwuji; Diantha Pillay; Patience Shamu; Mercy Murire; Susan Nzenze; Laura Ashleigh Cox; Saiqa Mullick
Journal:  J Antimicrob Chemother       Date:  2022-07-28       Impact factor: 5.758

8.  Antimicrobial Resistance of Neisseria Gonorrhoeae in a Newly Implemented Surveillance Program in Uganda: Surveillance Report.

Authors:  Meklit Workneh; Matthew M Hamill; Francis Kakooza; Emmanuel Mande; Jessica Wagner; Olive Mbabazi; Rodney Mugasha; Henry Kajumbula; Richard Walwema; Jonathan Zenilman; Patrick Musinguzi; Peter Kyambadde; Mohammed Lamorde; Yukari C Manabe
Journal:  JMIR Public Health Surveill       Date:  2020-06-10

Review 9.  Azithromycin resistant gonococci: a literature review.

Authors:  Awoke Derbie; Daniel Mekonnen; Yimtubezinash Woldeamanuel; Tamrat Abebe
Journal:  Antimicrob Resist Infect Control       Date:  2020-08-18       Impact factor: 4.887

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.